MS Pharma Inaugurates Biologics Manufacturing Facility in Saudi Arabia

MS Pharma has inaugurated a biologics manufacturing facility in Saudi Arabia.

With formulation, fill & finish, and lyophilization capabilities, this $50 million investment positions MS Pharma as a trusted partner for global pharmaceutical companies seeking market access to Saudi Arabia and the MENA region through local manufacturing and contract manufacturing solutions for broader international markets.

The factory is designed to meet the highest international regulatory standards, including EMA and U.S. FDA, and specializes in monoclonal antibodies and complex peptides. The plant also features the region’s first in-house bioanalytical testing laboratories, eliminating the need for overseas testing services and accelerating time-to-market for critical treatments.

“This launch is a defining milestone for MS Pharma and the MENA biopharmaceutical landscape,” said Ghiath Sukhtian, Chairman of MS Pharma. “We are proud to be driving forward a regional biologics platform that aligns with global healthcare demands and delivers high-value, complex medicines in collaboration with international partners.”

Kalle Känd, CEO of MS Pharma, added: “This facility goes beyond production—it’s a strategic enabler for global partnerships, offering regional access and contract manufacturing capacity for the international markets. It also unlocks localization incentives and strengthens our contribution to national and regional goals for local content, high-skilled employment, and technology transfer.”